A Phase 3 interventional study of Ritlecitinib 100 mg and Ritlecitinib 50 mg in Alopecia Areata, sponsored by Pfizer. Recruiting at 38 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.
Among the 17 studies in Alopecia Areata by Pfizer, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 3, and was the 16th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, China, Czechia and 6 more countries
Ages 6–14
Pfizer · Sites in Korea, Republic of
Ages 12+
Pfizer · Sites in United States, Canada, China and 8 more countries
Ages 12+
By country, each count listing its studies:
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6
First in 2016; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 336 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 175 across the 10 interventional studies, 375 across the 6 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Alopecia Areata by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Alopecia Areata by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate alopecia areata (AA).
This study is seeking participants who are
Participants will have a 2 in 3 chance of receiving ritlecitinib 50 mg and a 1 in 3 chance of receiving placebo. The placebo looks like the study medicine but does not contain any active ingredients. Participants will not know what you have been assigned to receive. They will take ritlecitinib or placebo once daily by mouth at home for 24 weeks (6 months). After 24 weeks, the assigned treatment may stay the same or be changed to ritlecitinib 50 mg or 100 mg. This change will depend on how participants' alopecia areata responds to the treatment. Participants will receive the newly assigned treatment for another 23 weeks.
About 4 weeks after the last dose, there will be a follow-up visit. At this visit, the team will check on your health. Participants will take part in this study for about 57 weeks. During this time, they will have study visits at the study clinic. Some study checks will be done by phone.
We will compare the experiences of people receiving ritlecitinib to those of people who do not. This will help us determine if ritlecitinib is safe and effective.
Key Inclusion Criteria
Key Exclusion Criteria
1. Diseases or conditions affecting hair loss, including:
Participants will receive 1 ritlecitinib 50 mg capsule QD orally from Day 1 to Week 24. At Week 24: Responders will be allocated to the below: Arm 1A (Ritlecitinib 50 mg R Group): 1 ritlecitinib 50 mg capsule QD and 1 placebo 100 mg capsule QD orally through Week 48. Non-Responders will be re-randomized to either of the below: Arm 1B (Ritlecitinib 50 mg NR→50 mg Group): 1 ritlecitinib 50 mg capsule QD and 1 placebo 100 mg capsule QD orally through Week 48. Arm 1C (Ritlecitinib 50 mg NR→100 mg Group): 1 ritlecitinib 100 mg capsule QD and 1 placebo 50 mg capsule QD orally through Week 48.
Drug: Ritlecitinib 100 mg · Drug: Ritlecitinib 50 mg
Participants will receive 1 placebo 50 mg capsule QD orally from Day 1 to Week 24 At Week 24: Responders will be allocated to the below: Arm 2A (Placebo R Group): 1 placebo 50 mg capsule QD and 1 placebo 100 mg capsule QD orally through Week 48. Non-Responders will be allocated to the below: Arm 2B (Placebo NR→Ritlecitinib 50 mg Group): 1 ritlecitinib 50 mg capsule QD and 1 placebo 100 mg capsule QD orally through Week 48.
Drug: Ritlecitinib 100 mg · Drug: Ritlecitinib 50 mg · Other: Placebo
100 mg capsule taken orally once daily
50 mg capsule taken orally once daily
Capsule matching either 50mg or 100 mg ritlecitinib capsule taken orally once daily
Difference in the proportion of Severity of Alopecia Tool (SALT) 0 responders at Week 24 between ritlecitinib 50 mg QD versus placebo
Time frame: Week 24
Difference in the proportion of SALT ≤5 responders at Week 24 between ritlecitinib 50 mg QD versus
Time frame: Week 24
Difference in the proportion of SALT ≤10 responders at Week 24 between ritlecitinib 50 mg QD versus
Time frame: Week 24
Difference in the proportion of SALT 75 responders at Week 24 between ritlecitinib 50 mg QD versus
Time frame: Week 24
Difference in the proportion of SALT 90 responders at Week 24 between ritlecitinib 50 mg QD versus
Time frame: Week 24
Difference in the mean change from baseline (CFB) in SALT score at applicable timepoints through Week 24 for ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18 and 24
Difference in the proportion of Patient Global Impression of Change (PGI-C) responders at Week 24 between ritlecitinib 50 mg QD versus placebo
Time frame: Week 24
Difference in the proportion of SALT 0 responders at applicable timepoints between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18
Difference in the proportion of SALT ≤10 responders at applicable timepoints between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18
Difference in the proportion of SALT ≤5 responders at applicable timepoints between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18
Difference in the proportion of SALT 75 responders at applicable timepoints between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18
Difference in the proportion of SALT 90 responders at applicable timepoints between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18
Difference in the mean CFB in SALT score at applicable timepoints between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18
Difference in the proportion of Eyebrow Assessment (EBA) responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18, 24
Difference in the proportion of Eyelash Assessment (ELA) responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18, 24
Difference in the proportion of PGI-C responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18
Difference in the proportion of Patient's Satisfaction with Hair Growth (P-SAT) responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18, 24
Difference in the proportion of Improvement in hair loss on each of the Alopecia Areata Patient Priority Outcomes (AAPPO) items 1-4 responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18, 24
Difference in the proportion of Improvement in Emotional Symptoms on each of the AAPPO items 5-8 responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18, 24
Difference in the proportion of Improvement in Activity Limitations on each of the AAPPO items 9-11 responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 8, 12, 18, 24
Proportion of participants with treatment emergent AEs, SAEs, and adverse events leading to discontinuation including those collected during the safety follow-up period
Time frame: Screening to Follow up period (up to week 57)
Proportion of responders for SALT 0 at appliable timepoints after Week 24
For each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Proportion of responders for SALT ≤10 at appliable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Proportion of responders for SALT ≤5 at appliable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Proportion of responders for SALT 75 at appliable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Proportion of responders for SALT 90 at appliable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Difference in the proportion of SALT 0 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Difference in the proportion of SALT≤10 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Difference in the proportion of SALT≤5 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Difference in the proportion of SALT75 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Difference in the proportion of SALT90 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Mean CFB in SALT score at applicable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Difference in the mean CFB in SALT score at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Proportion of responders for EBA at appliable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Proportion of responders for ELA at appliable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Difference in the proportion of EBA responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Difference in the proportion of ELA responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Proportion of PGI-C responders at applicable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Proportion of P-Sat responders at applicable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Proportion of responders for Improvement in hair loss on each of the AAPPO items 1-4 at applicable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Proportion of responders for Improvement in Emotional Symptoms on each of the AAPPO items 5-8 at applicable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Proportion of responders for Improvement in Activity Limitations on each of the AAPPO items 9-1 1 responders at applicable timepoints after Week 24
for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)
Time frame: Weeks 28, 36, and 48
Difference in the proportion of PGI-C responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Difference in the proportion of P-SAT responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Difference in the proportion of Improvement in hair loss on each of the AAPPO items 1-4 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Difference in the proportion of Improvement in Emotional Symptoms on each of the AAPPO items 5-8 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Difference in the proportion of Improvement in Activity Limitations on each of the AAPPO items 9-11 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group
Time frame: Weeks 28, 36, and 48
Proportion of participants with clinically significant abnormalities in clinical laboratory test values including those collected during the safety follow-up period
Time frame: Screening to Follow up period (up to 57 weeks)
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Jul 2026 (actual). Primary completion is estimated for Apr 2028, 20 months after the start.
Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's planned 20 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600